NVP 1402

Drug Profile

NVP 1402

Alternative Names: NVP-1402

Latest Information Update: 21 Sep 2016

Price : $50

At a glance

  • Originator Navipharm
  • Class
  • Mechanism of Action Undefined mechanism
  • Orphan Drug Status

    Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.

    No
  • On Fast track

    Fast track status is assigned by the US FDA so therapies with the potential to address unmet needs can move faster through development.

    No
  • New Molecular Entity Yes

Highest Development Phases

  • Preclinical CNS disorders

Most Recent Events

  • 07 Sep 2016 Navipharm Corporation plans a phase I pharmacokinetics trial in Healthy volunteers in South Korea (PO) (NCT02897726)
  • 03 Aug 2016 Preclinical trials in CNS disorders in South Korea (PO)
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top